Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade-Reference-Cited by-同舟云学术

Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade

Published:2022-05-26 Issue:5 Volume:127 Page:916-926
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Chen Tingting^ORCID,Yu Tong,Zhuang Shuping,Geng Yiding,Xue Junwen,Wang Jiayi,Ai Liqiang,Chen Bo,Zhao Zhangxiang^ORCID,Li Yawei,Wang Jinghao,Liang Haihai^ORCID,Xu Yan^ORCID,Gu Yunyan^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-022-01836-0.pdf

Reference31 articles.

1. Patel PS, Algouneh A, Hakem R. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene. 2021;40:3001–14.

2. Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020;159:887–98.

3. Yan S, Xuan J, Brajanovski N, Tancock MRC, Madhamshettiwar PB, Simpson KJ, et al. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. Br J Cancer. 2021;124:616–27.

4. Cai C. A Novel mechanism to induce BRCAness in cancer cells. Cancer Res. 2020;80:2977–8.

5. Gadducci A, Guerrieri ME. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: from the basic research to the clinic. Crit Rev Oncol Hematol. 2017;114:153–65.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering BRCAness Phenotype in Cancer: A Graph Convolutional Neural Network Approach with Layer-wise Relevance Propagation Analysis;2024-06-29

2. Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy;Cancer Research;2024-03-14

3. Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors;Frontiers in Immunology;2024-02-27

4. Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature;World Journal of Surgical Oncology;2024-02-09

5. Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy;2024-01-10